Dentin matrix protein 1 (DMP1) is a member of the Small Integrin-Binding LIgand Nlinked Glycoproteins (SIBLINGs) family, a group of proteins initially described as mineralized extracellular matrices components. More recently, SIBLINGs have been implicated in several key steps of cancer progression, including angiogenesis. Although proangiogenic activities have been demonstrated for two SIBLINGs, the role of DMP1 in angiogenesis has not been addressed yet. We demonstrated that this extracellular matrix protein induced the expression of VE-cadherin, a key regulator of intercellular junctions and contact inhibition of growth of endothelial cells that is also known to modulate VEGFR-2 activity, the major high affinity receptor for VEGF. DMP1 induced VE-cadherin and p27
INTRODUCTION
Dentin matrix protein 1 (DMP1) is a member of the Small Integrin-Binding LIgand Nlinked Glycoprotein (SIBLING) genes family, which also includes osteopontin (OPN), bone sialoprotein (BSP) and dentin sialophosphoprotein (DSPP) 1, 2 . DMP1 was originally considered to be dentin-specific 3 but later on, its expression was also detected in bone and in non-mineralized tissues such as salivary glands and kidney 4, 5 . While its precise biological activities have not been identified, this glycoprotein has been mainly associated with the regulation of extracellular matrix mineralization 6 . We and others have contributed to demonstrate the expression of SIBLINGs in human tumors with OPN and BSP being the two most studied in relation with cancer progression and metastasis development 1 studies allowed us to demonstrate the up-regulation of DMP1 in lung and breast human tumors 8, 9 and DSPP in prostate cancer 10 .
Angiogenesis is a multistep process in which activated endothelial cells of existing vessels migrate and proliferate in the perivascular stroma to form capillary sprouts. These sprouting endothelial cells stop proliferating, align, form tubes and deposit a basement membrane to finally yield operational new vessels 11 . Vascular endothelial (VE)-cadherin, the principal cell-cell junction molecule in endothelial cells 12 , is required for a normal vasculature development in the mouse embryo and for new vessel formation in the adult 13 . VE-cadherin engagement is associated with the cessation of proliferation commonly known as contact inhibition of growth 14 where endothelial cells show a reduced proliferative response to specific factors such as vascular endothelial growth factor (VEGF). Binding of VEGF to
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From vascular endothelial receptor 2 (VEGFR-2) is the principal extracellular signal triggering an angiogenic response and leads to VEGFR-2 dimerization and autophophorylation. One of the mechanisms of the contact inhibitory activity of VE-cadherin occurs through the modulation of VEGFR-2 signaling 15 . Src family kinases (SFKs) are involved in VEGFR-2 signaling and the regulation of angiogenesis 16 . VE-cadherin interacts with C-terminal Src kinase (Csk), an inhibitor of SFKs in vascular endothelial cells. Upon VEGF stimulation, VE-cadherin-Csk complex is disrupted thus allowing the activation of Src kinase and its downstream signaling 17 . Endothelial cell-matrix interactions mediated by integrins play a critical role in vascular development and angiogenesis 18 . One characteristic feature of the SIBLINGs is the presence of a highly conserved RGD motif in their primary structure 2 that is recognized by endothelial integrins. Indeed, DMP1 promotes α v β 3 -mediated cell attachment and migration 19 .
DMP1 has been also shown to interact with CD44 cell surface receptor 20 , detectable both on vascular endothelium in situ and on cultured human endothelial cells and that is involved in tumor angiogenesis 21 . While OPN 22 and BSP 23 display pro-angiogenic properties through their interaction with endothelial integrins, the question of a potential influence of DMP1 on the behavior of endothelial cells has never been addressed yet.
In the present work, we investigated whether DMP1 is involved in the multistep process required for the formation of new blood vessels by studying the effects of recombinant human DMP1 on human umbilical vein endothelial cells (HUVEC). Our data are the first demonstration of a CD44-dependent function of DMP1 in endothelial morphogenesis through VE-cadherin induction. We show that DMP1 mediated-VE-cadherin increase is accompanied by an arrest of proliferation in sparse HUVEC thus mimicking the contact inhibition of growth that occurs in endothelial cells cultured at high cell density. Because VEcadherin expression regulates VEGFR-2 signaling, we investigated further the role of DMP1
on VEGF-induced proliferation, migration and tubulogenesis responses. We demonstrate that
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Finally, we were able to demonstrate that DMP1 interferes with two in vivo angiogenesis models, one involving wound healing and the other tumor development.
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MATERIALS and METHODS

Cell culture and recombinant proteins. Human umbilical vein endothelial cells (HUVEC)
were isolated and maintained in culture as previously described 24 . Cells were cultured in MCDB131 medium (Gibco) supplemented with 20% FBS, 2mmol/L L-glutamine, 50µg/ml heparin and 50µg/ml Endothelium Cell Growth Supplement (ECGS) referred as complete medium thereafter. Recombinant human DMP1, VEGF165 and bFGF were purchased from R&D Systems.
Antibodies. Anti-p27
Kip1 and anti-pRb were from BD Pharmingen. Anti-phosphop27 Kip1 (Ser 10 ) was from Zymed Laboratories. Anti-Hsc 70, anti-p21, anti-VEGFR-2, antiphospho-VEGFR-2 and anti-phospho-VEGFR1 were from Santa Cruz Biotechnology. Anti-VEGFR-1, anti-β-actin were from Sigma-Aldrich. Anti-VE-cadherin, anti-phospho-VEcadherin(Y685), anti-Csk, anti-PARP and anti-α V -integrin were from BD Biosciences. Anti-PECAM-1 was from Dako. Anti-phospho-VE-cadherin(Y731)/(Y658) were from Invitrogen.
Anti-ZO-1, anti-phospho-Src(Y416)/(Y527) were from Cell Signaling. Anti-DMP1 was from Takara. For blocking experiments, HUVEC were incubated with RGD peptide (GRGDS,
and mouse purified IgG (Serotec) prior to DMP1 treatment.
Western blotting. Equal amounts of proteins were resolved by SDS-PAGE, blotted and membranes were first probed with the indicated antibodies and re-probed with β -actin or Hsc 70 antibodies. Scanned bands were quantified using ImageJ (http://rsb.info.nih.gov/ij/).
RNA interference. HUVEC (15x10 4 , 6-well plates) were grown overnight in complete medium. Cells were transfected with 100nmol/L of small interfering RNAs (siRNAs) using calcium phosphate precipitation method and cultured for 48h or treated during the last 24h of ) were deposited on the CAM of fertilized day 10 eggs and tumors developed after 5 days were harvested as we described previously 27 . Tumor volumes were calculated as described previously 28 . 
RESULTS
DMP1 induces HUVEC adhesion, migration and differentiation but inhibits proliferation
HUVEC adhered to DMP1 to a similar extent than to the other RGD-containing protein, vitronectin, while they did not adhere to control BSA. The addition of an RGD peptide completely inhibited adhesion to DMP1, suggesting that DMP1 mediates HUVEC attachment through molecular interaction with integrins ( Figure 1A ). When placed in the lower chamber of a modified Boyden chamber, DMP1 stimulated HUVEC migration ( Figure 1B ). To determine the importance of a concentration gradient for the observed migratory response, cell migration was evaluated when DMP1 was placed either in the top chamber only or in both chambers. DMP1 has chemotactic properties, inasmuch as placing this molecule in both chambers at the same concentration reduced maximal migration by 34%. However, because the absence of a concentration gradient did not totally abolish cell migration, we can also consider that DMP1 exhibits chemokinetic ability towards endothelial cells. We next showed that DMP1-treated HUVEC were less proliferative than control cells ( Figure 1C ). We assessed by Annexin-V assay ( Figure S1A ) and a western blot to PARP ( Figure S1B ) that DMP1-treated cells were not apoptotic.
Then, we tested the impact of DMP1 on tubulogenesis in a Matrigel in vitro assay. As early as 1h after seeding, we observed that DMP1-treated endothelial cells spread and attached on Matrigel when compared to control. Vessels counting after 4h demonstrated that DMP1-treated HUVEC rapidly formed a tubular network still maintained after 24h ( Figure 1D ).
Altogether these data indicate that DMP1 could act as a pro-differentiating factor for HUVEC and contributes to the organization and/or stability of developing endothelial tubular networks.
DMP1 blocks the cell cycle in G1, modulates the expression of cell cycle-related proteins and induces p27
Kip1 through CD44 ligation 1 1 We next investigated whether the decrease of HUVEC proliferation was due to an arrest of the cell cycle. Synchronized HUVEC were released with medium containing 20% serum in presence of DMP1 or mimosine, an inhibitor of DNA replication leading to mammalian cell cycle arrest in G1-phase 29 used as control. DMP1 treatment significantly impaired cell cycle progression after serum release, with an accumulation of HUVEC in the G1-phase from 70 to 82% and a decrease of S-phase cell population from 17 to 5% (Figure 2A ).
To investigate whether the DMP1 effect on the cell cycle was mediated through an interaction with α V β 3 or CD44, we used specific blocking antibodies. In DMP1-treated cells, the S-phase population was decreased to 28% when compared to the control S-phase cell population arbitrarily set as 100%. However, cells pre-treated with anti-CD44 proved to be able to enter the S-phase, with the population of S-phase cells being significantly increased to 74%. No significant changes were observed with cells pre-treated with anti-α V β 3 or control IgG ( Figure 2B ). Thus, the inhibitory effect of DMP1 on the cell cycle is mediated, at least in part, through CD44 receptor and not α
The cyclin dependent kinase (CDK) inhibitors p21 Cip1 and p27 Kip1 can bind and inhibit the kinase activities of several cyclin-CDK complexes and arrest cell growth at G1/S boundary. The expression of p27 Kip1 was induced by DMP1 in a dose-dependent manner ( Figure 2C ) whereas the expression of p21 Cip1 was unaffected ( Figure 2D ). Consistent with the cell cycle arrest observed in DMP1-treated HUVEC, these cells showed a significant decrease of phospho-pRb ( Figure 2E ). The importance of p27 Kip1 in DMP1-induced effect on HUVEC growth was further demonstrated by the use of specific siRNAs. We found that DMP1 treatment failed to inhibit the proliferation of p27 Kip1 silenced-HUVEC when compared to either mock-or irrelevant siRNA transfected cells ( Figure S2 ).
We next demonstrated that p27 Kip1 induction was abolished when cells were treated with anti-CD44 prior to DMP1 treatment while significant p27 Kip1 induction was still Figure 2F ). Our data are consistent with CD44 being the key receptor involved in mediating the observed effects of DMP1 on cell cycle arrest and on the increase of p27 Kip1 expression in HUVEC. Regarding p27 Kip1 , it has been shown that the phosphorylation on serine 10 increases its stability 30 . DMP1 treatment of HUVEC rapidly induced a significant increase of phospho-p27
Kip1
(Ser 10 ) while total p27
Kip1 level was unchanged ( Figure 2G ). After 24h, total p27 Kip1 level also increased, suggesting its accumulation over time.
DMP1 induces CD44-dependent VE-cadherin expression and mediates inhibition of growth in sparse HUVEC
VE-cadherin is a major homophilic cell-to-cell adhesion molecule involved in the control of blood vessel formation and contact inhibition of endothelial cell growth. Using immunofluorescence, we demonstrated that DMP1 treatment significantly induced the expression of VE-cadherin at the cell membrane already after 3h ( Figure 3A) . Western blot performed on membrane extracts showed a two-fold increase of VE-cadherin expression level in DMP1-treated HUVEC ( Figure 3B ). FACS analysis confirmed this increase whereas DMP1 did not affect surface expression of other endothelial cell-cell junction protein expression such as zonula-occludens-1 (ZO-1) and PECAM-1 ( Figure S3 ).
It has been previously reported that N-Cadherin 31 and E-cadherin 32 mediated signaling is involved in contact inhibition of growth by inducing p27 Kip1 expression and cell cycle arrest at the G1-phase. However, no direct evidence of an effect of VE-cadherin on p27 
DMP1 counteracts VEGF-induced angiogenesis
Knowing that VEGF is essential for angiogenic processes both in normal and pathological conditions 33 and based on our previous observations, we decided to investigate the effects of DMP1 on VEGF-induced proliferation, migration and tubulogenesis. Sparse and confluent cells were treated with DMP1 during 24h and then with VEGF another 24h. We observed that
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From DMP1 pre-treatment impaired VEGF-induced sparse cell proliferation in a dose-dependant manner when compared to VEGF-treated sparse cells ( Figure 4A ) while it did not affect confluent cells. We next studied the impact of DMP1 on VEGF-induced cell cycle progression. Synchronized HUVEC responded to VEGF release by a significant entry in Sphase when compared to control cells released with serum. However, the S-phase cell population corresponded to that of non released cells upon DMP1 treatment ( Figure 4B ). The migration of endothelial cells is a critical step during vessel formation. We showed that DMP1 impaired migration of cells towards VEGF when compared to control cells ( Figure   4C ).
To finally assess the effect of DMP1 on VEGF-induced angiogenesis, we tested the impact of DMP1 on VEGF-induced tubulogenesis. After 6h, we observed that DMP1 treatment impaired VEGF-induced tubular network formation on Matrigel ( Figure 4D ).
Interestingly, these DMP1 effects appear to be specific to VEGF-induced angiogenesis, as 
DMP1 inhibits VEGFR-2 phosphorylation through the induction of VE-cadherin expression
At the surface of endothelial cells, VEGFR-2 has been identified as the major mediator of VEGF-dependent signaling and cellular activities 34 . VEGFR-2 expression level was significantly increased while its phosphorylation was completely inhibited upon DMP1
treatment. Under the same conditions, DMP1 did not show any significant effect on VEGFR-1 expression nor phosphorylation ( Figure 5A ).
VE-cadherin has been shown to control contact inhibition of endothelial cell growth by inhibiting VEGFR-2 phosphorylation, notably through the recruitment of specific phosphatases 15 . Therefore, we postulated that the observed decrease of VEGFR-2 phosphorylation could be subsequent to the induction of VE-cadherin expression following 
DMP1 blocks VEGF-induced VEGFR-2 phosphorylation and inhibits Src activation
VEGFR-2 receptor is expressed and phosphorylated upon activation by its ligands. Therefore, we next evaluated whether DMP1 could impair VEGF influence on VEGFR-2. HUVEC were treated with DMP1 during 24h and challenged with VEGF (50ng/ml) during 10 minutes. To exert its pro-angiogenic activities, VEGF activates Src through phosphorylation of Tyr416 and dephosphorylation of Tyr527. Upon DMP1 addition, the phosphorylation of Src Tyr416 was reduced to almost basal level and that of Tyr527 was increased ( Figure 5D ), indicating that DMP1 counteracts VEGF-triggered Src activation.
DMP1 inhibits VEGF-mediated VE-cadherin down-regulation and phosphorylation
It is known that VE-cadherin undergoes both a decrease of expression and an inactivation through tyrosine phosphorylation by VEGF 36 . DMP1 impaired VEGF-mediated decrease of VE-cadherin expression ( Figure 5E ). As expected, VEGF induced the phosphorylation of VEcadherin on Tyr731, 658 and 685 while DMP1 alone did not affect its phosphorylation status.
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Interestingly, DMP1 treatment specifically reversed VEGF-induced VE-cadherin phosphorylation on Tyr685 ( Figure 5E ).
It has been shown that Src phospho-Tyr527 level is dictated by the activities of Cterminal Src Kinase (Csk) 37 which is recruited at the membrane by VE-cadherin. Accordingly, we found that DMP1 induced the expression of Csk in HUVEC sparse cultures and as such mimicked the induction of Csk that occurs in confluent cells ( Figure 5F ). Finally, we observed that, in good accordance with its Src kinase promoting activity, VEGF induced a significant decrease of Csk while DMP1 treatment proved to be able to counteract this effect ( Figure 5G ). The ability of DMP1 to block VEGF-triggered Src activation through the induction of Csk expression is consistent with its potent antagonistic role on VEGF-induced angiogenesis.
DMP1 inhibits angiogenesis in the choroidal neovascularization model in mice
To further investigate the anti-angiogenic effect of DMP1, we took advantage of the laserinduced choroidal neovascularization (CNV) model in which VEGF has been shown to be a major stimulator of subretinal angiogenesis 38 . In this experiment, mice were injected intravitreally with DMP1 (500nmol/L) on the day of the laser injuries. After 7 days, the whole-mount choroids were stained in order to reveal neoformed blood vessels. As shown in Figure 6A , DMP1 significantly limited the size of neovascularized ocular lesions when compared to control lesions. Quantification of the lesions showed a 30% decrease upon DMP1 treatment ( Figure 6A ).
Overexpression of DMP1 in glioma tumor cells decreases tumor growth and tumorangiogenesis in vivo
Hagedorn et al. 28 have established a robust and highly reproducible in vivo human tumor model that allows fast and precise analysis of the main steps of tumor progression and tumorassociated angiogenesis where human glioma cells U87-MG grafted onto the vascularized
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From chicken CAM develop into a tumor within a short period of time. DMP1-overexpressing U87-MG cells developed into tumors that were smaller and less vascularized, as they appeared much more white, than fully vascularized control tumors ( Figure 6B ). H&E as well as specific vasculature immunostaining confirmed that DMP1-overexpressing tumors were significantly less angiogenic than control tumors ( Figures 6C and 6D, respectively) . The estimation of tumor volume demonstrated that the experimental gliomas were significantly smaller upon DMP1 overexpression ( Figure 6E ). DMP1 western blot on glioma tumor extracts validated the overexpression of DMP1 in vivo ( Figure 6F ). In a previous study, we have investigated DMP1 expression by immunohistochemistry in human breast cancer tumors 9 . SIBLING proteins expression being generally associated with bad prognosis and poor survival for cancer patients 1 , we have been a little puzzled by the observation that patients with tumors expressing high levels of DMP1 presented with a better survival than patients with low DMP1-expressing tumors. In this study, we observed a striking impact of DMP1 on tumor growth and tumor-related angiogenesis in vivo. In fact, DMP1 inhibitory effect on both processes was comparable to that of siRNAs directed against VEGF as assessed using the same in vivo model in a previous study 27 . In light of these new data, it is tempting to speculate that high-DMP1 expressing tumors may be associated with limited neovessel formation as tumor-secreted DMP1 could favor endothelial cells differentiation at the expense of their proliferation. Arguing for this possibility is the observation that high-DMP1 expressing human tumors were consistently small sized 9 .
In conclusion, we demonstrate for the first time that DMP1 is implicated in endothelial cell morphogenesis in vitro indicating that secreted ECM proteins are endowed with specific functions that influence the dynamic balance controlling vessel growth. The other picture of this study is that DMP1 induces the up-regulation of VE-cadherin and VEGFR-2 inactivation thus specifically leading to impaired VEGF-mediated wound healing and tumor-associated angiogenesis in vivo. and 24 hours (40x). Phase contrast microscopy photomicrographs were taken at each time.
Shown below, the quantification of the assay was realized by counting the number of vessels from 2 representative fields from 2 replicates (n=3). **, p ≤ 0.005 versus control. n.s.
indicates not significant. 
